Entresto, a medication prescribed for heart failure, is manufactured by Novartis [1]. Its active ingredients are sacubitril and valsartan [2].
How Does Entresto Work for Heart Failure?
Entresto is a combination medication that works in two ways [2]. Sacubitril is a neprilysin inhibitor, and valsartan is an angiotensin II receptor blocker (ARB) [2]. Neprilysin helps break down natriuretic peptides, which are hormones that help the body get rid of salt and water and widen blood vessels [2]. By inhibiting neprilysin, Entresto increases the levels of these beneficial natriuretic peptides [2]. ARBs like valsartan block the effects of angiotensin II, a hormone that narrows blood vessels and causes salt and water retention [2]. Together, these actions help reduce strain on the heart [2].
When Will Entresto's Patents Expire?
The patent exclusivity for Entresto is a key concern for its future market access. According to DrugPatentWatch.com, Entresto's patents are set to expire in the coming years, opening the door for potential generic competition [3]. Specific patent expiry dates can vary by region and may be subject to legal challenges [3].
What Are the Potential Risks and Side Effects of Entresto?
Common side effects reported with Entresto include low blood pressure, high potassium levels, dizziness, and kidney problems [1]. In some cases, angioedema, a severe swelling of the face, lips, tongue, or throat, can occur [1]. Patients taking Entresto should not also take an ARB or an ACE inhibitor [2].
Can Other Companies Make Generic Versions of Entresto?
The development of generic versions of Entresto, also known as biosimilars, is contingent on patent expiries and regulatory approvals [3]. Once patents expire, other pharmaceutical companies may seek to market generic versions, potentially leading to lower costs [3].
What Are Alternative Treatments for Heart Failure?
Besides Entresto, other medications are used to manage heart failure. These include ACE inhibitors, ARBs, beta-blockers, diuretics, and mineralocorticoid receptor antagonists [4]. The choice of treatment depends on the specific type and severity of heart failure, as well as individual patient factors [4].